Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: The APOLLOtrial

European Heart Journal

Volumn 35, Issue 26, 2014, Pages 1743-1751

  Teo, Koon K ^a   Pfeffer, Marc ^b   Mancia, Giuseppe ^c   O'Donnell, Martin ^a,d   Dagenais, Gilles ^e   Diaz, Rafael ^f   Dans, Antonio ^g   Liu, Lisheng ^h   Bosch, Jackie ^a   Joseph, Philip ^a   Copland, Ingrid ^a   Jung, Hyejung ^a   Pogue, Janice ^a   Yusuf, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c SAN GERARDO HOSPITAL   (Italy)

^d NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^e LAVAL UNIVERSITY   (Canada)

^f Estudios Clinicos Latinoamerica ^*  (Argentina)

^g UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^h PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Aliskiren; Clinical trial; Combination therapy; Direct renin inhibitor; Lowering stage 1 hypertension in elderly

Indexed keywords

ALISKIREN; AMLODIPINE; HYDROCHLOROTHIAZIDE; PLACEBO; POTASSIUM; AMIDE; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE;

AGED; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD PRESSURE; BORDERLINE HYPERTENSION; BRONCHITIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAINTNESS; FEMALE; GASTROINTESTINAL DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; MEDICATION COMPLIANCE; MULTICENTER STUDY; PATHOPHYSIOLOGY;

AGED; AMIDES; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MEDICATION ADHERENCE; POTASSIUM; TREATMENT OUTCOME;

EID: 84921803349     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu079     Document Type: Article

References (18)

1. Cooper RS. Geographic patterns of hypertension: A global perspective. In: Black HR, Izzo JL (ed), Hypertension Primer, 3rd ed. American Heart Association Dallas, 2003, pp. 231-233
2. Lakatta EG. Aging, hypertension and the heart. In: Black H, Izzo JL (ed), Hypertension Primer, 3rd ed. Dallas, p166-169
3. World Health Organization/International Society of Hypertension. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on the management of hypertension. J Hypertens 2003;21:1983-1992
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, JonesDW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252
5. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension. J Hypertens 2007;25: 1105-1187
6. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009;27:923-934
7. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clement D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-2158
8. The Task Force for the management of arterial hypertension on the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC guidelines for the management of arterial hypertension. J Hypertens 2013;31:1281-1357
9. Nussberger J, Aubert J-F, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L. Renin inhibition by aliskiren prevents atherosclerosis progression. Comparison with irbesartan, atenolol, and amlodipine. Hypertension 2008;51:1306-1311
10. Brown MJ. Aliskiren. Circulation 2008;118:773-784
11. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, BedigianMP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation, 2005;111: 1012-1018
12. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, doubleblind trial. Lancet 2007;370:221-229
13. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, for the AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-2446
14. Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007;20: 11-20
15. Gheorghiade M,BohmM, Greene SJ, FonarowGC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz JX, Lesogor A, Maggioni AP, for the ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissionsamong patientshospitalized for heart failure. The ASTRONAUT Randomized Trial. JAMA 2013;309:1125-1135
16. TheONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559
17. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in highrisk patients. N Engl J Med 2000;342:145-153
18. Parving H-H, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA, for the ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-2213